US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 0.64 against a street estimate of 0.05 — a beat of 1180.0%.
Analysts rate Teva Pharma Industries Ltd ADR a buy (10 buy, 1 hold, 0 sell out of 11) with an average price target of $41.91.
CONFIDENT AUSTEDO, AJOVY, UZEDY all beat; Q2 revenue flat despite $1.1B generic REVLIMID loss. Raising guidance on three growth drugs. Pipeline advancing: olanzapine LAI Q4 2026, ecopipane H1 2027, Duvaqetilimab expanding into HS and fibrotic Crohn's. On track for 30% operating margin by 2027. Q2 2026 No regional revenue breakout given beyond AUSTEDO U.S. performance. Ex-U.S. generics lower on reduced launches and seasonality. Analysts pressed on payer dynamics post-IRA, anti-IL-15 mechanism vs. Forte, ecopipane differentiation, fibrotic Crohn's addressable market, and AUSTEDO inventory normalization. Management emphasized mandatory Medicare coverage, ligand-vs-receptor science rationale, unmet pediatric need, and confidence in gluten-challenge biopsy readout timing, while noting inventory drawdown remains Q3–Q4 focused. 2026-07-29…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 5.59% |
| Harel Insurance Invests & Fin Srvcs Ltd | 3.94% |
| Phoenix Financial Ltd | 3.67% |
| WCM Investment Management | 3.50% |
| MENORA MIVTACHIM HOLDINGS LIMITED | 3.40% |
| Clal Insurance Enterprises Holdings Ltd | 3.30% |
| Migdal Insurance & Financial Holdings Ltd | 3.25% |
| FMR Inc | 2.84% |
| Document | Date |
|---|---|
| Material agreement · Q3 2026 TEVA PHARMACEUTICAL INDUSTRIES LIMITED – 8-K SUMMARY HEADLINE NUMBERS • Total debt issuance: $4.7 billion across multiple tranches on September 16, | 2026-09-16 |
| Company announcement · Q3 2026 TEVA PHARMACEUTICAL INDUSTRIES LIMITED - 8-K SUMMARY HEADLINE NUMBERS • No financial performance metrics disclosed in this filing • Filing date: Sep | 2026-09-14 |
| Reg FD disclosure · Q3 2026 TEVA PHARMACEUTICAL INDUSTRIES LIMITED – 8-K SUMMARY HEADLINE NUMBERS • Total debt issuance: $4.7 billion across 5 separate senior note offerings • | 2026-09-11 |
| Company announcement · Q3 2026 TEVA PHARMACEUTICAL INDUSTRIES LIMITED — 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Teva has reorganized its segment reporting structure effective | 2026-09-03 |
| Current report · Q3 2026 TEVA PHARMACEUTICAL INDUSTRIES LIMITED – 8-K SUMMARY HEADLINE NUMBERS • Report Date: August 31, 2026 • Company: Teva Pharmaceutical Industries Limit | 2026-09-03 |
| Quarterly report · Q2 2026 TEVA PHARMACEUTICAL INDUSTRIES LIMITED – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Net Revenues (6M 2026): $8,124 million vs. $8,067 million (6M 2025) | 2026-07-29 |
| Results announced · Q3 2026 TEVA PHARMACEUTICAL Q2 2026 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Q2 2026 total revenues: $4.1 billion, down 1% year-over-year in USD (dow | 2026-07-29 |
| Shareholder vote results · Q2 2026 TEVA PHARMACEUTICAL INDUSTRIES LIMITED – 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held May 28, 2026 • Board election: Dr. Sol J. Barer received | 2026-05-28 |
Readable in the app.
| Announcement | Date |
|---|---|
| Received $500 million milestone payment for anti-TL1A Phase 3 study initiation Teva Pharmaceutical reported financial activities for 2025 with mixed signals. On the positive side, the company received $500 million in milestone payments from a licensing collaboration fo | 2026-09-03 |
| Acquires Emalex Biosciences for $700 million; raises 2026 outlook for innovative brands Teva Pharmaceutical delivered Q2 2026 revenues of $4.1 billion (down 1% year-over-year in dollars, 3% in local currency), but showed strong progress on its 'Pivot to Growth' strategy. The co | 2026-07-29 |
| FY2025 revenues $17.3B +4% YoY; targets 30% operating margin by 2027 Teva Pharmaceutical reported strong 2025 results, achieving its third consecutive year of growth with revenues of $17.3 billion (4% increase YoY). The company's innovative portfolio is perfo | 2026-01-28 |
| 2025 results and forward-looking outlook for 2026 and beyond provided Teva Pharmaceutical announced its 'Pivot to Growth' strategy at the J.P. Morgan Healthcare Conference, showcasing transformation progress and forward guidance through 2030. KEY 2025 EXPECTE | 2026-01-12 |
| Raises 2025 Austedo outlook and non-GAAP EPS guidance Teva Pharmaceutical reported Q3 2025 revenues of $4.5 billion, up 3% year-over-year, marking its 11th consecutive quarter of growth. The company's innovative portfolio is driving results, wi | 2025-11-05 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Teva Pharma Industries Ltd ADR — free to start.
Google PlayApp StoreData updated 2026-09-18.